



The Villain Returns: Disease Relapse Following Transplant, MRD Assessment and Treatment Strategies

Friday, November 9, 2018

10:45 a.m. – 12:00 p.m.

Speakers

Philip McCarthy, MD, Veronika Bachanova, MD, PhD

Session Objectives

At the conclusion of this session, attendees will be able to:

1. Discover the incidence and continuing challenges of hematopoietic malignancy relapse following allogeneic hematopoietic stem cell transplantation.
2. Compare innovative methodologies to detect pre- and post-HCT minimal residual disease (MRD).
3. Analyze the promise of innovative cellular therapeutic strategies to treat and prevent relapse in HCT patients.
4. Evaluate the strategies employed when utilizing new targeted immunotherapeutic approaches to treat disease relapse.

Conflict of Interest/Financial Disclosure

The planners and speaker(s) have disclosed the following financial relationships and/or conflicts of interest:

Philip McCarthy, MD	Celgene, Honoraria, Advisory Board; Karyopharm, Honoraria, Advisory Board; Celgene, Institute research Support, Research; Medscape, Honoraria, Generating content for online lecture; Axis, Honoraria, Generating content for MM lecture
Veronika Bachanova, MD, PhD	None
Alan Howard	Jazz Pharmaceuticals, Travel/Lodging, Consultant
Misty Evans	Jazz Pharmaceuticals, Monetary, Speakers Bureau